Efficacy and Safety of Bulevirtide Monotherapy Given at 2 mg or 10 mg Dose Level Once Daily for Treatment of Chronic Hepatitis Delta: Week 48 Primary Endpoint Results from a Phase 3 Randomized, Multicenter, Parallel Design Study
暂无分享,去创建一个
S. Zeuzem | P. Lampertico | H. Wedemeyer | M. Brunetto | A. Blank | P. Andreone | A. Osinusi | M. Cornberg | J. Flaherty | V. Chulanov | S. Aleman | Qi An | P. Bogomolov | O. Sagalova | V. Suri | T. Stepanova | D. Manuilov | N. Mamonova | N. Geyvandova | V. Morozov | Julian Schulze zur Wiesch